Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Positive Buy Recommendation for Axsome Therapeutics Driven by Promising AXS-05 Efficacy in Alzheimer's Agitation
Strong Commercial Performance and Growth Potential Drive Buy Rating for Axsome Therapeutics' Auvelity
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $115
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $106